April 13-18

American Academy of Neurology

Boston, MA (Hybrid): 22-27 April, 2023

American Academy of Neurology

American Academy of Neurology

Ofatumumab – B Cell Therapy

Longer-term Safety and Efficacy of Ofatumumab in People With Relapsing Multiple Sclerosis for Up to 6 years

Wiendl H et al.
Poster: P9.010
Abstract

Longer-term (up to 6 Years) Efficacy of Ofatumumab in People with Recently Diagnosed and Treatment-Naive Relapsing Multiple Sclerosis

Pardo G et al.
Oral Presentation: S31.003
Abstract

Ofatumumab Reduces Clinical and Radiological Activity in People with Recently Diagnosed Treatment-Naive Relapsing Multiple Sclerosis Irrespective of Baseline Serum Neurofilament Light Chain Levels

Pardo G et al.
Poster: P9.008
Abstract

Prognostic Value of On-Treatment Serum Neurofilament Light Chain for New or Enlarging T2 Lesions in People With Relapsing Multiple Sclerosis: Pooled Analysis of the ASCLEPIOS I/II Trials

Leist T et al.
Oral Presentation: S42.003
Abstract

Baseline Serum Neurofilament Light Chain Levels Predict Future Disease Activity Irrespective of Race/Ethnicity: Results from the Phase 3 ASCLEPIOS I/II Trials

Freeman J et al.
Poster: P9.006
Abstract

Prognostic Value of Serum Neurofilament Light Chain for Disease Activity in Patients with Relapsing Multiple Sclerosis: Results from Subgroup Analysis Based on Body Mass Index and Age from the Phase 3 ASCLEPIOS I/II Trials

Cross A et al.
Poster: P6.011
Abstract

Patient and Physician Perspectives on the Wearing-Off Effect in Multiple Sclerosis: Results from Structured Interviews

Alvarez E et al.
Poster: P1.015
Abstract

Meta-Analysis for Neurofilament Light Chain as a Biomarker in Mouse Experimental Autoimmune Encephalomyelitis Studies

Kieseier B et al.
Oral Presentation: S17.008
Abstract

OLIKOS Study: 6-Month Interim Efficacy and Safety in Patients With Relapsing Multiple Sclerosis Who Switched to Subcutaneous Ofatumumab From Intravenous Anti-CD20 Therapies

Alvarez E et al.
Poster: P10.006
Abstract

Real-world Persistence of Ofatumumab vs Self-injectable or Oral Disease-modifying Therapies in Patients with Multiple Sclerosis

Hersh C et al.
Poster: P5.012
Abstract

Real-world Effectiveness, Tolerability and Safety of Ofatumumab at 12-month Follow-up

Hersh C et al.
Poster: P9.014
Abstract

Outcomes of COVID-19 in Ofatumumab-Treated Patients With RMS: Data From the ALITHIOS Open-Label Extension Study

Montalban X et al.
Poster: P1.010
Abstract

Long-Term Effect of Ofatumumab on Serum Immunoglobulin Levels in Patients With Relapsing Multiple Sclerosis

Bar-Or A et al.
Poster: P9.007
Abstract

B-Cell Depletion and Efficacy Outcomes of Ofatumumab Are Consistent Across Different Body Mass Index Categories: Insights From ASCLEPIOS I and II Trials

Coyle P et al.
Poster: P9.002
Abstract

Ofatumumab in Different RMS Patient Populations in Everyday Clinical Practice in Germany

Nelles G et al.
Poster: P2.013
Abstract

Effects of Ofatumumab Treatment on Immune Cells Landscape in Patients With Relapsing-remitting Multiple Sclerosis

Zhang C et al.
Poster: P7.014
Abstract

Immunoglobulin Level Changes in Patients with Multiple Sclerosis Treated with Anti-CD20 Monoclonal Antibodies

Alvarez E et al.
Poster: P9.011
Abstract
Remibrutinib – BTK Inhibitor

The Bruton's Tyrosine Kinase Inhibitor Remibrutinib Exhibits No Impact on Serum Immunoglobulin Levels: Insights from Chronic Spontaneous Urticaria

Bermel R et al.
Poster: P10.018
Abstract

Safety of Remibrutinib Across Immune-Mediated Diseases Supports Development in Multiple Sclerosis

Kieseier B et al.
Poster: P8.015
Abstract
MS - Portfolio

Multiple Sclerosis Treatment and Holistic Patient Care Consensus by the Spanish Society of Neurology

Oreja C et al.
Poster: P3.013
Abstract

Rationale, Patient Characteristics, and First Interim Insights from NeofiLos – A Prospective Data Collection to Evaluate Utility and Added Value of Serum NfL in MS

Katja A et al.
Poster: P7.016
Abstract

MLR ID: 428197

Ofatumumab – B Cell Therapy
Ofatumumab Efficacy & Safety

Effect of Longer term Ofatumumab Treatment on Disability Worsening and Brain Volume Change

Cohen J. et.al
Oral Presentation: S16.009
Abstract

Five-Year Safety of Ofatumumab in People Living With Relapsing Multiple Sclerosis

Cohen J. et.al
Poster: P8.004
Abstract

Pregnancy Outcomes in Patients With MS Following Exposure to Ofatumumab: Updated Results From the Novartis Safety Database

Bove R. et.al
Poster: P9.014
Abstract

Cognitive Processing Speed Predicts Disability Milestones In Multiple Sclerosis

Howart D. et.al
Poster: P5.014
Abstract

Improvement in Cognitive Processing Speed With Ofatumumab in Patients With Relapsing Multiple Sclerosis

Benedict R. et.al
Poster: P6.005
Abstract

Tracking the Immune Response to SARS-CoV-2 mRNA Booster Vaccination in an Open-label Multicenter Study in Participants With Relapsing Multiple Sclerosis Treated With Ofatumumab s.c. (KYRIOS Clinical Trial)

Bopp T. et.al
Poster: P2.016
Abstract

Compliance and Persistence With Ofatumumab Treatment in patients with Relapsing Multiple Sclerosis in Clinical Trials for Up to 4 Years

Alvarez E. et.al
Poster: P8.002
Abstract

Long-term Effect of Ofatumumab Treatment on Serum Neurofilament Light Chain Levels and NEDA-3 Status in Patients With RMS: Results From ASCLEPIOS I/II and ALITHIOS

Alvarez E. et.al
Poster: P6.013
Abstract

Efficacy of Early Ofatumumab vs Late Switch From Teriflunomide: Subgroup Analysis of the ALITHIOS Open-label Extension Study by Previous Disease-Modifying Therapy Exposure and Age

Wiendl H. et.al
Poster: P6.016
Abstract

Wearing-off Effect Toward the End of Treatment Cycles in Patients With MS Receiving High-Efficacy Disease-Modifying Therapies: Data From Social Media Listening

Clement I. et.al
Poster: P3.009
Abstract
Ofatumumab & Preclinical

Comparative Pharmacology of Ofatumumab versus Ocrelizumab in Humanised CD20 Transgenic Mice

Bigaud M. et.al
Oral Presentation: S9.007
Abstract
Remibrutinib – BTK inhibitor
Remibrutinib Efficacy & Safety

Remibrutinib: A Novel BTKi in Development For MS with a Favorable Safety Profile in Various Autoimmune Disorders.

Williams M. et.al
Poster: P7.015
Abstract

Remibrutinib, a Novel Bruton Tyrosine Kinase Inhibitor, Exhibits Improved Target Selectivity and Potency in vitro

Kieseier B. et.al
Poster: P8.003
Abstract

Remibrutinib Inhibits Neuroinflammation Driven by B Cells and Myeloid Cells in Preclinical Models of Multiple Sclerosis

Kieseier B. et.al
Poster: P2.013
Abstract
Siponimod – S1P Modulator
Siponimod Efficacy and Safety

AMASIA study: Real World Insights on the Impact of Early Siponimod Treatment on SPMS Patients in Germany

Hoffmann O. et.al
Poster: P8.013
Abstract

AMA-VACC: Clinical Trial Assessing the Immune Response to SARS-CoV-2 mRNA Vaccines and Booster Vaccination in Siponimod Treated Patients With Secondary Progressive Multiple Sclerosis

Ziemssen T. et.al
Poster: P12.004
Abstract

Siponimod Stabilizes Physical Disability Scores in People Living With Secondary Progressive Multiple Sclerosis After 2 Years of Treatment: Analysis From the Novartis Global Managed Access Program

Cox G. et.al
Poster: P8.010
Abstract
Fingolimod – S1P Receptor Modulator
Fingolimod Efficacy

Final Results of the PANGAEA 2.0 Study: Treatment Benefits of Fingolimod for Active RRMS Patients Switching from Other DMTs

Weiss C. et.al
Poster: P6.009
Abstract

MLR ID: 279416

2022 Presentations
 

Ofatumumab – B Cell Therapy
Ofatumumab & COVID-19 Vaccination

[P1.288] Tracking the Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab s.c. (KYRIOS Clinical Trial)

Groth M. et.al
Abstract
Ofatumumab Efficacy & Safety

[P5.004] Long-term Efficacy of Ofatumumab in Patients With Relapsing Multiple Sclerosis

Hauser S. et.al
Abstract

[S14.004] Long-term Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis

Hauser S. et.al
Abstract

[P3.004] Risk Perception in Multiple Sclerosis: Reasons for Switching Treatment Between High Efficacy and Non-high Efficacy Disease-modifying Therapies

Siefer G. et.al
Abstract

[P7.011] Injection-Related Reactions with Subcutaneous Administration of Ofatumumab in Relapsing Multiple Sclerosis: Data from Clinical Studies and Post Marketing Experience

Kramer J. et.al
Abstract

[S14.008] Efficacy of Ofatumumab on Microglial Activity in Patients with Relapsing forms of Multiple Sclerosis: Interim Analysis

Singhal T. et.al
Abstract

[P1.350] Cost Effectiveness of Ofatumumab in Comparison with Other Disease Modifying Therapies and Best Supportive Care for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada

Mouallif S. et.al
Abstract
Ofatumumab & Pregnancy

[P4.007] Pregnancy Outcomes in Patients With Multiple Sclerosis Following Exposure to Ofatumumab

Hellwig K. et.al
Abstract
Siponimod - S1P Receptor Modulator
Siponimod & COVID-19 Vaccination

[P1.307] AMA-VACC: Clinical Trial Assessing the Immune Response to SARS-CoV-2 mRNA Vaccines in Siponimod Treated Patients with Secondary Progressive Multiple Sclerosis

Rauser B. et.al
Abstract
Siponimod Efficacy & Safety

[P5.002] Analyses of the Effect of Baseline Age on the Efficacy and Safety of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis from the Phase 3 EXPAND Study

Hua L. et.al
Abstract

[P5.006] Cognitive Processing Speed Predicts Disease Progression in Secondary Progressive Multiple Sclerosis: Post Hoc Analysis from the EXPAND Study

Penner I. et.al
Abstract

[P6.001] Effect of Siponimod on Disability Progression as Measured by the Ambulation Score, a Subscore of the Neurostatus-EDSS: Post hoc Analysis of the EXPAND Trial in SPMS

D’Souza M. et.al
Abstract

[P6.004] Estimating Long-term Effect of Siponimod on Disability Progression Versus Virtual Placebo in SPMS Using RPSFT Model: EXPAND Data up to 7 years

Cree B. et.al
Abstract

[P6.007] Innovative Comparative Study Assessing the Effect of Siponimod on Reactive Microglia/Astrocytes in Patients With Secondary Progressive Multiple Sclerosis: Study Design

Zivadinov R. et.al
Abstract

[P7.007] Safety and Tolerability of Conversion to Siponimod With and Without Titration in Patients with Advancing Forms of Relapsing Multiple Sclerosis: Interim Results of the Phase 3b EXCHANGE Study

Bar-Or A. et.al
Abstract

[P8.006] Safety and Tolerability of Conversion to Siponimod in Patients with Advancing Relapsing Multiple Sclerosis: A Subgroup Analysis by Race and Ethnicity of EXCHANGE Interim Data

Bar-Or A. et.al
Abstract

[P8.007] Safety and Efficacy of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis Identifying as Hispanic from the Phase 3 EXPAND Study

Cohan S. et.al
Abstract

[P16.008] Estimating the Profile of Responders to Treatment In the Phase 3 EXPAND Trial: Do Different Patients Show Benefits on Different Outcomes?

Bovis F. et.al
Abstract

[S14.010] MRI Activity versus Relapses as Markers of Disease Activity in SPMS: Data from Adelphi Real-World MS Disease Specific Programme and The Phase 3 EXPAND Study

Giovannoni G. et.al
Abstract
Remibrutinib – BTK Inhibitor
Remibrutinib Efficacy & Safety

[P7.003] Phase 3 REMODEL I/II Trials: Effectiveness, Safety, and Tolerability of Remibrutinib in Patients with Relapsing Multiple Sclerosis

Wiendl H. et.al
Abstract
MS Treatment & Care
Patient-Reported Outcomes

[P10.004] Discordance Between Neurologists and People With Multiple Sclerosis on the Perception of the Presence and Burden of Cognitive Impairment

Penner I. et.al
Abstract

April 17-22, 2021, Virtual Meeting
 

Comparable Ofatumumab Treatment Outcomes in Patients across Racial/Ethnic Groups in the ASCLEPIOS I/II and APOLITOS studies

Poster presentation
Abstract

Ofatumumab Reduces Disability Progression Independent of Relapse Activity in Patients with Relapsing Multiple Scelrosis

Poster presentation
Abstract

Sustained Efficacy of Ofatumumab in Relapsing Multiple Sclerosis Patients: Results from Extended Treatment in the Phase 2 APOLITOS Study

Poster presentation
Abstract

Comparative Safety Assessment of Ofatumumab using Data from ASCLEPIOS I/II versus a Historical Propensity-adjusted Placebo Arm

Poster presentation
Abstract

Characteristics and Outcome of COVID-19 in Patients with Relapsing Multiple Sclerosis Receiving Ofatumumab

Poster presentation
Abstract

Prognostic Value of Serum NfL for Subclinical Disease Activity and Worsening in Patients with RMS: Results from Phase 3 ASCLEPIOS I and II Trials

Poster presentation
Abstract

Effect of Ofatumumab on Pregnancy, Parturition and Lactation in Cynomolgus Monkeys

Poster presentation
Abstract

Baseline MRI Predictors of Cognitive Processing Speed in Participants with Secondary Progressive Multiple Sclerosis from the Phase 3 EXPAND study

Poster presentation
Abstract

Gray Matter Volume and Myelination Assessed by Magnetization Transfer Ratio Predict Disease Progression in Secondary Progressive Multiple Sclerosis: Exploratory Analyses from the EXPAND Study

Poster presentation
Abstract

Long-Term Effect of Siponimod on MRI Outcomes in SPMS: Analyses from the EXPAND Study up to 5 Years

Poster presentation
Abstract

A Functional Composite Endpoint to Characterize Disease Progression in Patients with Active or Non- active Secondary Progressive Multiple Sclerosis

Poster presentation
Abstract

Development and Usability Testing of a Patient-based Digital Tool to Understand Early Signs of Changes in Multiple Sclerosis Symptoms and Progression: Your MS Questionnaire

Poster presentation
Abstract

Siponimod Demonstrates Pro- remyelination Effects in the Mouse Cuprizone- Intoxication Model

Poster presentation
Abstract

Plasma Neurofilament Light Chain and Glial Fibrillary Acidic Protein Levels Are Prognostic of Disability Worsening: A Biosignature That Helps Differentiating Active From Non-active SPMS

Oral presentation
Abstract

Modelling disability progression in patients with secondary progressive multiple sclerosis shows non-linearity of EDSS changes over time

Poster presentation
Abstract

Characterization of changes in Multiple Sclerosis patient care in Germany during the COVID-19 pandemic

Poster presentation
Abstract

First-hand experience with Ofatumumab at ASCLEPIOS study sites in Germany

Poster presentation
Abstract

Ofatumumab as a potential first-line therapy for relapsing multiple sclerosis in Germany

Poster presentation
Abstract

National African American Multiple Sclerosis Registry: Advancing Equitable Care and Outcomes for African Americans with Multiple Sclerosis

Poster presentation
Abstract

OLIKOS Study Design: Exploring Maintained Ofatumumab Efficacy in Relapsing MS Patients who Transition from Intravenous Anti-CD20 Therapy

Poster presentation
Abstract

Adherence and Compliance with Subcutaneous Administration of Ofatumumab in Relapsing Multiple Sclerosis

Poster presentation
Abstract

Effect of Ofatumumab on Serum Immunoglobulin Levels and Infection Risk in Relapsing Multiple Sclerosis (RMS) Patients from the Phase 3 ASCLEPIOS I and II Trials

Poster presentation
Abstract

Characterization of patient and treatment characteristics in SPMS and at risk for SPMS patients in clinical routine: The PANGAEA 2.0 EVOLUTION study

Poster presentation
Abstract

Analyses of the Effect of Baseline Age on the Efficacy and Safety of Siponimod in Patients with Active SPMS from the Phase 3 EXPAND Study

Poster presentation
Abstract

Analyses of the Effect of Disease Duration on the Efficacy and Safety of Siponimod in Patients with Active SPMS from the Phase 3 EXPAND Study

Poster presentation
Abstract

Siponimod First-Dose Effects in Patients with SPMS Receiving Concomitant Selective Serotonin Reuptake Inhibitor (SSRI) Therapy

Poster presentation
Abstract

Safety and Tolerability of Conversion to Siponimod in Patients with Relapsing Multiple Sclerosis: Interim Results of the EXCHANGE Study

Poster presentation
Abstract

June 06−08, 2020, Virtual Meeting
 

Long-term Efficacy and Safety of Siponimod in Patients with SPMS: EXPAND Extension Analysis Up to 5 Years

Oral presentation: S40.003
Abstract

Plasma Glial Fibrillary Acidic Protein Correlates with Characteristics of Advanced Disease and Treatment Response in Secondary Progressive Multiple Sclerosis

Oral presentation: S10.006
Abstract

Magnetization Transfer Imaging in Secondary Progressive Multiple Sclerosis Patients Treated with Siponimod: Results from the Phase 3 EXPAND Study

Oral presentation: S40.006
Abstract

Siponimod Reduces Grey Matter Atrophy in Patients with Secondary Progressive Multiple Sclerosis: Subgroup Analyses from the EXPAND Study

Oral presentation: S40.005
Abstract

Siponimod Penetrates, Distributes and Acts on the Central Nervous System: Translational Insights

Poster presentation: P13.1-015
Abstract

Subcutaneous Anti-CD20 Antibody Treatment Delays Gray Matter Atrophy in Human Myelin Oligodendrocyte Glycoprotein-Induced Experimental Autoimmune Encephalomyelitis Mice

Poster presentation: P14.1-001
Abstract

Siponimod: From Understanding Mode of Action to Differentiation Versus Fingolimod

Poster presentation: P12.1-006
Abstract

Ofatumumab Reduces Disability Progression Independent of Relapse Activity in Patients with Relapsing Multiple Sclerosis

Oral presentation: S40.004
Abstract

Onset of B-cell Depletion and Suppression of MRI Activity with Ofatumumab Treatment in Relapsing Multiple Sclerosis: The APLIOS Study

Poster presentation: P8.1-001
Abstract

Ofatumumab Versus Teriflunomide in Patients with Relapsing Multiple Sclerosis: Phase 3 ASCLEPIOS I and II Trials

Abstract

B-cell Depletion and Efficacy Outcomes with Ofatumumab: Subgroup Analysis From the Pooled Phase 3 ASCLEPIOS I and II Trials

Poster presentation: P7.1-013
Abstract

First Results from PANGAEA 2.0 EVOLUTION: State of the Art Management of Patients with Secondary Progressive Multiple Sclerosis (SPMS) or at Risk for SPMS to Identify Key Parameters in Daily Clinical Practice for an Early and Unified Diagnosis

Poster presentation: P12.1-021
Abstract

Correlations Between Four Common Measures of Cognition in Patients With Secondary Progressive Multiple Sclerosis

Poster presentation: P10.1-014
Abstract

Effect of Siponimod on Disability in EXPAND Re-examined with Two New Subscales of the Expanded Disability Status Scale in Patients with SPMS

Poster presentation: S5.008
Abstract

Assessment and Follow-up of the Response to Disease Modifying Treatments in Multiple Sclerosis: Spanish Expert Consensus

Poster presentation: P9.1-015
Abstract

QUANTUM – Quantitative and Standardized Imaging in Daily Clinical Routine of MS Patients

Poster presentation: P2.1-017
Abstract

Study for the Validation of the FeetMe® Integrated Sensor Insole System Compared to GAITRite® System to Assess the Characteristics of the Gait in Patients with Multiple Sclerosis

Poster presentation: P14.1-019
Abstract

Changes in Immune cell Profile, Clinical and Safety Outcomes in Fingolimod-treated Patients With Relapsing Multiple Sclerosis in the FLUENT Study: 12 Month Results

Poster presentation: P9.1-005
Abstract

Prevalence of Serious Adverse Pregnancy Outcomes After Exposure to Interferon Beta Before or During Pregnancy: Stratification by Characteristics of Pregnant Women with MS in a Register-based Cohort study in Finland and Sweden

Poster presentation: P11.1-005
Abstract

First Full Analysis of the ESSENCE Data Set Presents a Cross Section of the SPMS Patient Management in Germany

Poster presentation: P5.1-002
Abstract
Cookie Settings